Traveler’s Diarrhea- Pipeline Insight, 2022

DelveInsight’s, “Traveler’s Diarrhea- Pipeline Insight, 2022,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Traveler’s Diarrhea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage

Traveler’s Diarrhea Understanding
Traveler’s Diarrhea: Overview
TD is a clinical syndrome that can result from a variety of intestinal pathogens. Bacterial pathogens are the predominant risk, thought to account for up to 80%–90% of TD. Intestinal viruses may account for at least 5%–15% of illnesses, although multiplex molecular diagnostic assays increase their detection. Bacteria are the most common cause of TD. Overall, the most common pathogen identified is enterotoxigenic Escherichia coli, followed by Campylobacter jejuni, Shigella spp., and Salmonella spp. Enteroaggregative and other E. coli pathotypes are also commonly found in cases of TD. There is increasing discussion of Aeromonas spp., Plesiomonas spp., and newly recognized pathogens (Acrobacter, Larobacter, enterotoxigenic Bacteroides fragilis) as potential causes of TD as well. Giardia is the main protozoal pathogen found in TD. Entamoeba histolytica is a relatively uncommon cause of TD, and Cryptosporidium is also relatively uncommon. TD occurs equally in male and female travelers and is more common in young adult travelers than in older travelers. In short-term travelers, bouts of TD do not appear to protect against future attacks, and >1 episode of TD may occur during a single trip. In environments in warmer climates where large numbers of people do not have access to plumbing or latrines, the amount of stool contamination in the environment will be higher and more accessible to flies. Inadequate electrical capacity may lead to frequent blackouts or poorly functioning refrigeration, which can result in unsafe food storage and an increased risk for disease. In destinations in which effective food handling courses have been provided, the risk for TD has been demonstrated to decrease. However, even in developed countries, pathogens such as Shigella sonnei have caused TD linked to handling and preparation of food in restaurants. Bacterial and viral TD presents with the sudden onset of bothersome symptoms that can range from mild cramps and urgent loose stools to severe abdominal pain, fever, vomiting, and bloody diarrhea, although with norovirus vomiting may be more prominent.

""Traveler’s Diarrhea- Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Traveler’s Diarrhea pipeline landscape is provided which includes the disease overview and Traveler’s Diarrhea treatment guidelines. The assessment part of the report embraces, in depth Traveler’s Diarrhea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Traveler’s Diarrhea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Traveler’s Diarrhea R&D. The therapies under development are focused on novel approaches to treat/improve Traveler’s Diarrhea.

Traveler’s Diarrhea Emerging Drugs Chapters
This segment of the Traveler’s Diarrhea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Traveler’s Diarrhea Emerging Drugs
IMM124E:Immuron
IMM-124E is a first-in class, oral polyclonal antibody therapy developed to target the endotoxin lipopolysaccharide (LPS) and other pathogenic bacterial components in the human gastrointestinal tract reducing LPS-related inflammation and systemic translocation. The drug is in Phase III clinical studies for the treatment of Traveler's diarrhea in individuals traveling to endemic areas for ETEC exposure.
LMN101: Lumen Bioscience
LMN-101 is a cocktail of neutralizing monoclonal antibody-like protein biologics designed to bind and neutralize the primary causes of traveler's diarrhea: the bacterial pathogens Campylobacter jejuni and enterotoxigenic E. coli. The drug is in Phase II clinical studies for the treatment of Traveler's diarrhea.
Further product details are provided in the report……..

Traveler’s Diarrhea: Therapeutic Assessment
This segment of the report provides insights about the different Traveler’s Diarrhea drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Traveler’s Diarrhea
There are approx. 4+ key companies which are developing the therapies for Traveler’s Diarrhea. The companies which have their Traveler’s Diarrhea drug candidates in the most advanced stage, i.e. Phase III include, Immuron.
Phases
DelveInsight’s report covers around 4+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Traveler’s Diarrhea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal
Molecule Type

Products have been categorized under various Molecule types such as
Oligonucleotide
Peptide
Small molecule
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Traveler’s Diarrhea: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Traveler’s Diarrhea therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Traveler’s Diarrhea drugs.

Traveler’s Diarrhea Report Insights
Traveler’s Diarrhea Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs
Traveler’s Diarrhea Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Traveler’s Diarrhea drugs?
How many Traveler’s Diarrhea drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Traveler’s Diarrhea?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Traveler’s Diarrhea therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Traveler’s Diarrhea and their status?
What are the key designations that have been granted to the emerging drugs?


Key Players
Nippon Shinyaku
Immuron
Eveliqure Biotechnologies
Lumen Bioscience
Scandinavian Biopharma
Sigmoid Pharma Limited





Key Products
Prulifloxacin
IMM 124E
Campylobacter jejuni/Escherichia coli oral vaccine
Escherichia coli/Shigella oral vaccine
LMN-101
Traveller's diarrhoea vaccine
Oral vaccines

Companies

Nippon Shinyaku
Immuron
Eveliqure Biotechnologies
Lumen Bioscience
Scandinavian Biopharma
Sigmoid Pharma Limited